Emergent BioSolutions Inc. (0IGA.L)
USD 5.19
(2.98%)
USD 5.19
(2.98%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -760.5 Million USD | -239.81% |
| 2022 | -223.8 Million USD | -201.96% |
| 2021 | 219.5 Million USD | -28.22% |
| 2020 | 305.8 Million USD | 461.1% |
| 2019 | 54.5 Million USD | -13.08% |
| 2018 | 62.7 Million USD | -24.09% |
| 2017 | 82.59 Million USD | 59.52% |
| 2016 | 51.77 Million USD | -17.65% |
| 2015 | 62.87 Million USD | 71.12% |
| 2014 | 36.74 Million USD | 18.01% |
| 2013 | 31.13 Million USD | 32.35% |
| 2012 | 23.52 Million USD | 2.19% |
| 2011 | 23.01 Million USD | -55.47% |
| 2010 | 51.69 Million USD | 66.0% |
| 2009 | 31.14 Million USD | 50.59% |
| 2008 | 20.68 Million USD | -9.83% |
| 2007 | 22.93 Million USD | 0.63% |
| 2006 | 22.79 Million USD | 44.41% |
| 2005 | 15.78 Million USD | 37.59% |
| 2004 | 11.47 Million USD | 157.57% |
| 2003 | 4.45 Million USD | -87.76% |
| 2002 | 36.39 Million USD | 6668.95% |
| 2001 | -554 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -283.1 Million USD | -3245.56% |
| 2024 Q1 | 9 Million USD | 118.18% |
| 2023 Q3 | -265.9 Million USD | -1.76% |
| 2023 Q4 | -49.5 Million USD | 81.38% |
| 2023 Q2 | -261.3 Million USD | -42.79% |
| 2023 Q1 | -183 Million USD | -107.95% |
| 2023 FY | -760.5 Million USD | -239.81% |
| 2022 Q2 | -56.4 Million USD | -1424.32% |
| 2022 Q1 | -3.7 Million USD | -101.95% |
| 2022 FY | -223.8 Million USD | -201.96% |
| 2022 Q3 | -75.7 Million USD | -34.22% |
| 2022 Q4 | -88 Million USD | -16.25% |
| 2021 FY | 219.5 Million USD | -28.22% |
| 2021 Q1 | 69.7 Million USD | -62.41% |
| 2021 Q2 | 4.6 Million USD | -93.4% |
| 2021 Q3 | -32.7 Million USD | -810.87% |
| 2021 Q4 | 189.3 Million USD | 678.9% |
| 2020 Q2 | 92.7 Million USD | 841.6% |
| 2020 Q3 | 39.5 Million USD | -57.39% |
| 2020 Q1 | -12.5 Million USD | -126.65% |
| 2020 Q4 | 185.4 Million USD | 369.37% |
| 2020 FY | 305.8 Million USD | 461.1% |
| 2019 Q1 | -26 Million USD | -664.71% |
| 2019 FY | 54.5 Million USD | -13.08% |
| 2019 Q2 | -9.5 Million USD | 63.46% |
| 2019 Q3 | 43.2 Million USD | 554.74% |
| 2019 Q4 | 46.9 Million USD | 8.56% |
| 2018 Q3 | 20.9 Million USD | -58.28% |
| 2018 Q2 | 50.1 Million USD | 1120.78% |
| 2018 FY | 62.7 Million USD | -24.09% |
| 2018 Q1 | -4.9 Million USD | -114.46% |
| 2018 Q4 | -3.4 Million USD | -116.27% |
| 2017 Q2 | 4.61 Million USD | -55.98% |
| 2017 FY | 82.59 Million USD | 59.52% |
| 2017 Q1 | 10.48 Million USD | -71.96% |
| 2017 Q4 | 33.94 Million USD | 1.17% |
| 2017 Q3 | 33.55 Million USD | 626.84% |
| 2016 Q3 | 21.34 Million USD | 294.94% |
| 2016 Q1 | 3.99 Million USD | -88.03% |
| 2016 FY | 51.77 Million USD | -17.65% |
| 2016 Q4 | 37.39 Million USD | 75.22% |
| 2016 Q2 | -10.94 Million USD | -374.29% |
| 2015 FY | 62.87 Million USD | 71.12% |
| 2015 Q4 | 33.34 Million USD | -9.73% |
| 2015 Q3 | 36.94 Million USD | 162.01% |
| 2015 Q2 | 14.1 Million USD | 165.52% |
| 2015 Q1 | -21.52 Million USD | -171.46% |
| 2014 Q3 | 21.83 Million USD | 334.12% |
| 2014 Q4 | 30.11 Million USD | 37.94% |
| 2014 FY | 36.74 Million USD | 18.01% |
| 2014 Q1 | -20.23 Million USD | -232.94% |
| 2014 Q2 | 5.02 Million USD | 124.85% |
| 2013 Q3 | 13.49 Million USD | 28.68% |
| 2013 FY | 31.13 Million USD | 32.35% |
| 2013 Q1 | -8.06 Million USD | -150.05% |
| 2013 Q4 | 15.22 Million USD | 12.83% |
| 2013 Q2 | 10.48 Million USD | 230.04% |
| 2012 FY | 23.52 Million USD | 2.19% |
| 2012 Q4 | 16.1 Million USD | 143.42% |
| 2012 Q3 | 6.61 Million USD | -13.3% |
| 2012 Q2 | 7.63 Million USD | 211.76% |
| 2012 Q1 | -6.82 Million USD | -123.83% |
| 2011 Q4 | 28.65 Million USD | 1750.03% |
| 2011 Q1 | -21.39 Million USD | -181.52% |
| 2011 Q2 | 14.21 Million USD | 166.41% |
| 2011 Q3 | 1.54 Million USD | -89.1% |
| 2011 FY | 23.01 Million USD | -55.47% |
| 2010 Q2 | 9.8 Million USD | 288.74% |
| 2010 Q1 | 2.52 Million USD | -40.41% |
| 2010 Q3 | 13.12 Million USD | 33.77% |
| 2010 Q4 | 26.24 Million USD | 100.05% |
| 2010 FY | 51.69 Million USD | 66.0% |
| 2009 Q2 | 14.84 Million USD | 33.48% |
| 2009 FY | 31.14 Million USD | 50.59% |
| 2009 Q4 | 4.23 Million USD | 346.15% |
| 2009 Q3 | 949 Thousand USD | -93.61% |
| 2009 Q1 | 11.11 Million USD | 664.19% |
| 2008 Q1 | 7.02 Million USD | -74.68% |
| 2008 FY | 20.68 Million USD | -9.83% |
| 2008 Q4 | 1.45 Million USD | -85.99% |
| 2008 Q3 | 10.38 Million USD | 472.23% |
| 2008 Q2 | 1.81 Million USD | -74.16% |
| 2007 Q3 | 2.84 Million USD | 157.35% |
| 2007 Q4 | 27.74 Million USD | 875.08% |
| 2007 Q1 | -2.69 Million USD | -110.3% |
| 2007 FY | 22.93 Million USD | 0.63% |
| 2007 Q2 | -4.96 Million USD | -84.42% |
| 2006 Q3 | -1.11 Million USD | 0.18% |
| 2006 Q4 | 26.12 Million USD | 2453.96% |
| 2006 FY | 22.79 Million USD | 44.41% |
| 2006 Q2 | -1.11 Million USD | 0.0% |
| 2006 Q1 | -1.11 Million USD | -111.67% |
| 2005 Q3 | 2.08 Million USD | 0.0% |
| 2005 Q2 | 2.08 Million USD | 0.0% |
| 2005 Q1 | 2.08 Million USD | -27.34% |
| 2005 FY | 15.78 Million USD | 37.59% |
| 2005 Q4 | 9.53 Million USD | 357.39% |
| 2004 Q3 | 2.86 Million USD | 0.0% |
| 2004 Q1 | 2.86 Million USD | 0.0% |
| 2004 Q2 | 2.86 Million USD | 0.0% |
| 2004 FY | 11.47 Million USD | 157.57% |
| 2004 Q4 | 2.86 Million USD | 0.0% |
| 2003 FY | 4.45 Million USD | -87.76% |
| 2002 FY | 36.39 Million USD | 6668.95% |
| 2001 Q1 | -3.7 Million USD | 95.8% |
| 2001 Q2 | -261.3 Million USD | -6962.16% |
| 2001 Q3 | -32.7 Million USD | 87.49% |
| 2001 FY | -554 Thousand USD | 0.0% |
| 2001 Q4 | -88 Million USD | -169.11% |
| 2000 Q4 | -88 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| uniQure N.V. | -308.47 Million USD | -146.533% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -1303.447% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -759.507% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | -115.997% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | -175.418% |
| Cara Therapeutics, Inc. | -118.51 Million USD | -541.702% |
| Imunon, Inc. | -19.51 Million USD | -3797.007% |
| Dynavax Technologies Corporation | -6.38 Million USD | -11803.271% |
| Editas Medicine, Inc. | -153.21 Million USD | -396.348% |
| FibroGen, Inc. | -284.23 Million USD | -167.563% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | -71.27% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -1702.175% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 404.565% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | -41.89% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 57888.754% |
| Verastem, Inc. | -87.36 Million USD | -770.466% |
| Zoetis Inc. | 2.34 Billion USD | 132.445% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 121.011% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | -194.961% |
| Homology Medicines, Inc. | -53.74 Million USD | -1315.068% |
| Nektar Therapeutics | -276.05 Million USD | -175.488% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -785.383% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -1807.928% |
| Perrigo Company plc | -12.7 Million USD | -5888.189% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | -263.444% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 91.194% |
| Illumina, Inc. | -1.16 Billion USD | 34.496% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 112.686% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 156.001% |
| Heron Therapeutics, Inc. | -110.55 Million USD | -587.868% |
| Waters Corporation | 642.23 Million USD | 218.415% |
| Biogen Inc. | 1.16 Billion USD | 165.498% |
| Evolus, Inc. | -61.68 Million USD | -1132.877% |
| Adicet Bio, Inc. | -142.65 Million USD | -433.093% |
| bluebird bio, Inc. | -211.91 Million USD | -258.874% |
| Geron Corporation | -184.12 Million USD | -313.03% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | -72.746% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | -401.702% |
| Myriad Genetics, Inc. | -112 Million USD | -579.018% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | -58.045% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 196.415% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -1605.03% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 553.637% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 119.236% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 161.331% |
| OPKO Health, Inc. | -188.86 Million USD | -302.673% |
| Exelixis, Inc. | 207.76 Million USD | 466.039% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 816.507% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -1500.884% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | -217.884% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | -107.625% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 370.07% |
| Blueprint Medicines Corporation | -506.98 Million USD | -50.005% |
| Insmed Incorporated | -749.56 Million USD | -1.459% |
| TG Therapeutics, Inc. | 12.67 Million USD | 6101.42% |
| Incyte Corporation | 597.59 Million USD | 227.259% |